All News
Filter News
Found 188 articles
-
Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
1/24/2019
Board members bring diverse experience tailored to the distinct opportunities and strategies of each new company
-
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
1/14/2019
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with relapsed or refractory colorectal cancer (CRC) who have been previously treated with standard of care (SOC) therapy.
-
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
12/21/2018
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx).
-
CytRx Corporation Reports Third Quarter 2018 Financial Results
11/2/2018
Quarter Marked by Centurion's Filing of a Provisional Patent for Breakthrough Personalized Medicine Companion Diagnostic to Accompany LADR Assets
-
Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
10/31/2018
Aldoxorubicin Being Studied in NantCell Clinical Trials in Combination with Immune-Based Therapy for the Treatment of Squamous Cell Carcinoma, Metastatic Pancreatic and Triple Negative Breast Cancers
-
CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
10/29/2018
CytRx Corporation announced that it will report financial results for the quarter ended September 30, 2018 on Friday, November 2, 2018.
-
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)
9/28/2018
Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease Type C (NPC).
-
CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
9/13/2018
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received a milestone payment of $250,000 (USD) from Orphazyme A/S (CPH: ORPHA).
-
CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease
5/23/2018
Centogene, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced a clinical development collaboration with Orphazyme A/S.
-
Capital Increase of 11,380 Shares (Equivalent to Approximately 0.06% of the Existing Shares) in Orphazyme A/S as a Result of an Issue of Bonus Shares to KLSDC and UCLB
1/29/2018
The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association.
-
Orphazyme: Publication of Manuscript Related to Phase II Trial Results for Arimoclomol in Patients With SOD1 ALS
1/25/2018
The manuscript highlights arimoclomol’s favorable safety profile and provides data on efficacy that supports the continued development of arimoclomol in a Phase II/III trial.
-
Orphazyme's Arimoclomol for NPC Receives Rare Pediatric Disease Designation
1/19/2018
NPC is a genetic disease affecting around 1 in 120,000 newborns.
-
Ablynx Announces Board Changes
1/8/2018
Ablynx today announced that Dr Peter Fellner, who has served as Chairman since 2013, has decided to resign from the Board with immediate effect.
-
Orphazyme A/S Release: Major Shareholder Announcement
12/18/2017
With reference to company announcement no. 5/2017 dated November 16, 2017 regarding the result of the IPO of Orphazyme and company announcement no. 10/2017 dated November 16, 2017, Orphazyme hereby announces that it has received the following notification pursuant to section 29 of the Danish Securities Trading Act regarding Novo Holdings A/S' holding of shares in Orphazyme.
-
Orphazyme Assumes Sponsorship of Phase II/III sIBM Trial
12/15/2017
The trial was conceived by expert investigators at KU Medical Center and UCL to assess the efficacy and safety of arimoclomol for the treatment of sIBM.
-
Orphazyme A/S: Major Shareholder Announcement - Nov. 16, 2017
11/16/2017
The company has received the following notifications pursuant to section 29 of the Danish Securities Trading Act regarding the existing major shareholders' direct and indirect respective holdings of shares in Orphazyme.
-
Orphazyme A/S: New Share-Based Incentive Programme
11/16/2017
Orphazyme has today implemented a new long-term incentive programme.
-
Orphazyme Receives Orphan Drug Designation To Arimoclomol for Inclusion Body Myositis From the FDA
11/7/2017
As described in the offering circular published by Orphazyme A/S on 6 November 2017, the Company applied to the FDA for the designation in September 2017.
-
Dr Nanna Lüneborg, Principal Of Novo Ventures, Joins Inventiva's Board
5/30/2017
-
Orphazyme Completes Enrollment Of Patients For Phase III Clinical Trial In Niemann-Pick Type C Disease
5/11/2017